Your browser doesn't support javascript.
loading
A phase 2 study of everolimus combined with trastuzumab and paclitaxel in patients with HER2-overexpressing advanced breast cancer that progressed during prior trastuzumab and taxane therapy.
Hurvitz, Sara A; Dalenc, Florence; Campone, Mario; O'Regan, Ruth M; Tjan-Heijnen, Vivianne C; Gligorov, Joseph; Llombart, Antonio; Jhangiani, Haresh; Mirshahidi, Hamid R; Tan-Chiu, Elizabeth; Miao, Sara; El-Hashimy, Mona; Lincy, Jeremie; Taran, Tetiana; Soria, Jean-Charles; Sahmoud, Tarek; André, Fabrice.
Affiliation
  • Hurvitz SA; Department of Medicine, Hematology/Oncology, UCLA Jonsson Comprehensive Cancer Center, 10945 Le Conte Avenue, PVUB Suite 3360, Los Angeles, CA, 90095, USA, shurvitz@mednet.ucla.edu.
Breast Cancer Res Treat ; 141(3): 437-46, 2013 Oct.
Article in En | MEDLINE | ID: mdl-24101324
Increased activation of the PI3K/Akt/mTOR pathway is a common factor in putative mechanisms of trastuzumab resistance, resulting in dysregulation of cell migration, growth, proliferation, and survival. Data from preclinical and phase 1/2 clinical studies suggest that adding everolimus (an oral mTOR inhibitor) to trastuzumab plus chemotherapy may enhance the efficacy of, and restore sensitivity to, trastuzumab-based therapy. In this phase 2 multicenter study, adult patients with HER2-positive advanced breast cancer resistant to trastuzumab and pretreated with a taxane received everolimus 10 mg/day in combination with paclitaxel (80 mg/m(2) days 1, 8, and 15 every 4 weeks) and trastuzumab (4 mg/kg loading dose followed by 2 mg/kg weekly), administered in 28-day cycles. Endpoints included overall response rate (ORR), progression-free survival (PFS), overall survival (OS), and safety. Fifty-five patients were enrolled; one remained on study treatment at the time of data cutoff. The median number of prior chemotherapy lines for advanced disease was 3.5 (range 1-11). The ORR was 21.8 %, the clinical benefit rate was 36.4 %, the median PFS estimate was 5.5 months (95 % confidence interval [CI]: 4.99-7.69 months), and the median OS estimate was 18.1 months (95 % CI: 12.85-24.11 months). Hematologic grade 3/4 adverse events (AEs) included neutropenia (25.5 % grade 3, 3.6 % grade 4), anemia (7.3 % grade 3), and thrombocytopenia (5.5 % grade 3, 1.8 % grade 4). Nonhematologic grade 3/4 AEs included stomatitis (20.0 %), diarrhea (5.5 %), vomiting (5.5 %), fatigue (5.5 %), and pneumonia (5.5 %), all grade 3. These findings suggest that the combination of everolimus plus trastuzumab and paclitaxel is feasible, with promising activity in patients with highly resistant HER2-positive advanced breast cancer. This combination is currently under investigation in the BOLERO-1 phase 3 trial.
Subject(s)

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2013 Document type: Article Country of publication: Netherlands

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Receptor, ErbB-2 Type of study: Clinical_trials Limits: Adult / Aged / Aged80 / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2013 Document type: Article Country of publication: Netherlands